Next Steps for Immunotherapies, Cell Therapies in Oncology Next Steps for Immunotherapies, Cell Therapies in Oncology

At ESMO 2017, Drs Zimmermann, Svane, and Coukos discuss successes and setbacks in immuno-oncology.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Related Links:

In this study, we developed two kinds of Y-shaped double-stranded DNA nanostructures (Y-DNAs), including a single unit composed of three DNA strands (YS-DNA) and a ligated multiunit complex formed by crosslinking each YS-DNA (YL-DNA), and investigated whether they have immunostimulatory activity in innate immune cells. YS-DNA and YL-DNA induced the production of immune cytokines such as IL-12 and TNF-α and the expression of costimulatory molecules such as CD80 and CD86 in primary mouse dendritic cells and macrophage cells (RAW264.7 cells). A Coprecipitation study demonstrated that YL-DNA was directly associated with ...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Publication date: April 2019Source: Biomedicine &Pharmacotherapy, Volume 112Author(s): Meiqi Zhao, Manyu Luo, Yueqing Xie, Hua Jiang, Cedric Cagliero, Ninghuan Li, Hao Ye, Mingyuan Wu, Shuai Hao, Tianyuan Sun, Hui Yang, Mengxiao Zhang, Tong Lin, Huili Lu, Jianwei ZhuAbstractRecombinant human interleukin-15 (IL-15) is a potent cancer immunotherapeutic candidate due to its excellent immune stimulating effects. Previous work demonstrated that IL-15 appeared with short half-life in circulation system, while the complex with its receptor can prolong the half-life as well as benefit its activities in vivo. Therefore, IL-15 c...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Epicutaneous immunotherapy for peanut allergy resulted in significantly more responses than placebo, but failed to meet a primary trial endpoint; the clinical meaning of the findings is unclear.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
Mercy Health-Cincinnati ’s Jewish Hospital is partnering with the physician group OHC Inc. to offer a new kind of immunotherapy for adults with certain types of blood cancer. The hospital in Kenwood and Linwood-based OHC are the first in Greater Cincinnati to provide Chimeric Antigen Receptor T-Cell Therapy, also known as CAR-T.  The therapy involves a doctor removing some of a patient’s immune system cells, modifying them in a laboratory so they will recognize and kill cancer, and then infusing…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
Conclusion: Maintenance therapy in NSCLC continues to be an important therapeutic line to improve outcome in patients with metastatic and recurrent disease.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Karishma R. Rajani, Lucas P. Carlstrom, Ian F. Parney, Aaron J. Johnson, Arthur E. Warrington, Terry C. Burns
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: 21 February 2019Source: Cell, Volume 176, Issue 5Author(s): Shashi Gujar, John Bell, Jean-Simon DialloOncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.
Source: Cell - Category: Cytology Source Type: research
(Osaka University) An Osaka University-led research team assayed T cell cytotoxicity in tumor tissue in lung cancer, along with normal lung tissue and peripheral blood. They found associations of tumor T-cell cytotoxicity with smoking and cytokine levels. They also revealed that T-cell cytotoxicity in peripheral blood correlated with that in tumors, and also with the effectiveness of nivolumab in cancer immunotherapy. These findings provide a simple tool for predicting immune checkpoint inhibitor efficacy in individual lung cancer patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
AbstractPurpose of ReviewFood allergy is a growing health problem worldwide that impacts millions of individuals. Current treatment options are limited and strict dietary avoidance remains the standard of care. Immunotherapy using whole, native allergens is under active clinical investigation but harbors the risk of severe side effects including anaphylaxis. Newer food-specific therapies with hypoallergenic proteins may potentially offer safer treatment alternatives, and this review seeks to investigate the evidence supporting the use of these modalities.Recent FindingsThe utilization of different methods to alter allergen...
Source: Current Allergy and Asthma Reports - Category: Allergy & Immunology Source Type: research
ConclusionThe rate of FV among ICI-related myocarditis cases was lower than controls on ICIs who did not develop myocarditis. In those who developed myocarditis related to an ICI, there was less myocardial injury and a lower risk of MACE among those who were administered the FV.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Health | Hematology | Immunotherapy